Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1999 9
2000 10
2001 13
2002 19
2003 20
2004 28
2005 38
2006 41
2007 52
2008 51
2009 45
2010 51
2011 47
2012 49
2013 47
2014 45
2015 47
2016 49
2017 35
2018 37
2019 27
2020 33
2021 21
2022 21
2023 18
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

766 results

Results by year

Filters applied: . Clear all
Page 1
Salmeterol/fluticasone propionate combination.
Spencer CM, Jarvis B. Spencer CM, et al. Drugs. 1999 Jun;57(6):933-40; discussion 941-3. doi: 10.2165/00003495-199957060-00010. Drugs. 1999. PMID: 10400406 Review.
Fixed combination salmeterol/fluticasone propionate in 3 different fluticasone propionate dosage strengths administered via the Diskus powder inhaler does not result in any untoward interaction that affects the pharmacodynamic or pharmaco …
Fixed combination salmeterol/fluticasone propionate in 3 different fluticasone propionate dosage s …
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Wedzicha JA, et al. N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15. N Engl J Med. 2016. PMID: 27181606 Free article. Clinical Trial.
RESULTS: A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol-fluticasone group. Indacaterol-glycopyrronium showed not only noninferiority but also superiority to salmeterol-fluticasone in reducing …
RESULTS: A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol-fluticasone …
Pharmacological treatment of COPD - New evidence.
Pires N, Pinto P, Marçal N, Ferreira AJ, Rodrigues C, Bárbara C; GI DPOC Interest Group on Chronic Obstructive Pulmonary Disease. Pires N, et al. Pulmonology. 2019 Mar-Apr;25(2):90-96. doi: 10.1016/j.pulmoe.2018.10.005. Epub 2018 Nov 28. Pulmonology. 2019. PMID: 30502972 Free article. Review.
Fluticasone Propionate/Salmeterol MDPI (AirDuo RespiClick()): A Review in Asthma.
Paik J, Scott LJ, Pleasants RA. Paik J, et al. Clin Drug Investig. 2018 May;38(5):463-473. doi: 10.1007/s40261-018-0644-2. Clin Drug Investig. 2018. PMID: 29582249 Review.
In 12-week, phase III trials in patients aged 12 years with persistent asthma, all three dosages of fluticasone propionate/salmeterol MDPI treatment produced significant improvements in lung function and other asthma symptoms compared with fluticasone …
In 12-week, phase III trials in patients aged 12 years with persistent asthma, all three dosages of fluticasone propionate/ …
Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.
Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE; GOAL Investigators Group. Bateman ED, et al. Am J Respir Crit Care Med. 2004 Oct 15;170(8):836-44. doi: 10.1164/rccm.200401-033OC. Epub 2004 Jul 15. Am J Respir Crit Care Med. 2004. PMID: 15256389 Clinical Trial.
A 1-year, randomized, stratified, double-blind, parallel-group study of 3,421 patients with uncontrolled asthma compared fluticasone propionate and salmeterol/fluticasone in achieving two rigorous, composite, guideline-based measures of control: totall …
A 1-year, randomized, stratified, double-blind, parallel-group study of 3,421 patients with uncontrolled asthma compared fluticasone …
Cost-effectiveness of salmeterol xinafoate/fluticasone propionate combination inhaler in chronic asthma.
Doull I, Price D, Thomas M, Hawkins N, Stamuli E, Tabberer M, Gosden T, Rudge H. Doull I, et al. Curr Med Res Opin. 2007 May;23(5):1147-59. doi: 10.1185/030079907x187982. Curr Med Res Opin. 2007. PMID: 17519082
OBJECTIVE: To determine where in the treatment steps recommended by the British Thoracic Society and Scottish Intercollegiate Guidelines Network (BTS/SIGN) Asthma Guideline it is cost-effective to use salmeterol xinafoate/fluticasone propionate comb …
OBJECTIVE: To determine where in the treatment steps recommended by the British Thoracic Society and Scottish Intercollegiate Guidelines Net …
Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD.
Muiser S, Imkamp K, Seigers D, Halbersma NJ, Vonk JM, Luijk BHD, Braunstahl GJ, van den Berg JW, Kroesen BJ, Kocks JWH, Heijink IH, Reddel HK, Kerstjens HAM, van den Berge M. Muiser S, et al. Thorax. 2023 May;78(5):451-458. doi: 10.1136/thorax-2022-219620. Epub 2023 Feb 1. Thorax. 2023. PMID: 36725331 Clinical Trial.
We aimed to investigate its efficacy compared with fixed-dose fluticasone/salmeterol in chronic obstructive pulmonary disease (COPD). METHODS: Patients with COPD and 1 exacerbation in the previous 2 years were randomly assigned to open-label MART (Spiromax budesonid …
We aimed to investigate its efficacy compared with fixed-dose fluticasone/salmeterol in chronic obstructive pulmonary disease …
Salmeterol/fluticasone propionate: a review of its use in asthma.
McKeage K, Keam SJ. McKeage K, et al. Drugs. 2009;69(13):1799-828. doi: 10.2165/11202210-000000000-00000. Drugs. 2009. PMID: 19719334 Review.
The greater efficacy achieved with salmeterol/fluticasone propionate versus fluticasone propionate alone was sustained for 1 year in a well designed trial. Salmeterol/fluticasone propionate is also associated with a corticos …
The greater efficacy achieved with salmeterol/fluticasone propionate versus fluticasone propionate alone …
Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis.
Maneechotesuwan K, Singh D, Fritscher LG, Dursunoglu N, P G A, Phansalkar A, Aggarwal B, Pizzichini E, Chorazy J, Burnett H. Maneechotesuwan K, et al. Respir Med. 2022 Nov;203:106993. doi: 10.1016/j.rmed.2022.106993. Epub 2022 Sep 21. Respir Med. 2022. PMID: 36257125 Free article. Review.
OBJECTIVE: This network meta-analysis (NMA) compared fixed-dose, twice daily fluticasone propionate/salmeterol (FP/Sal) vs. inhaled corticosteroid (ICS) and other ICS/long-acting beta-agonists (LABA) treatments, including when administered using maintenance a …
OBJECTIVE: This network meta-analysis (NMA) compared fixed-dose, twice daily fluticasone propionate/salmeterol (FP/Sal) …
Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.
Markham A, Jarvis B. Markham A, et al. Drugs. 2000 Nov;60(5):1207-33. doi: 10.2165/00003495-200060050-00012. Drugs. 2000. PMID: 11129128 Review.
The long-acting beta2-agonist salmeterol and the corticosteroid fluticasone propionate are available as a combination inhalation device for the treatment of persistent asthma. ...Salmeterol/fluticasone is more cost effective than monother …
The long-acting beta2-agonist salmeterol and the corticosteroid fluticasone propionate are available as a combinatio …
766 results